Skip to main content

Table 2 Male and female patient characteristics

From: Investigating the risk of bone fractures in elderly patients with type 2 diabetes mellitus: a retrospective study

 

Males

Females

P value

n = 1371

n = 741

 

Age (years)

76.4 ± 6.7

78.1 ± 7.6

< 0.001

  ≥ 65–< 75, n (%)

680 (49.6)

264 (35.6)

 

  ≥ 75, (n, %)

691 (50.4)

477 (64.4)

 

BMI (kg/m2)

23.1 ± 3.9

23.2 ± 4.6

0.28

  < 25, n (%)

999 (72.9)

507 (68.4)

 

  ≥ 25, n (%)

372 (27.1)

234 (31.6)

 

HbA1c (%)

7.1 ± 1.1

7.1 ± 1.4

0.24

  < 7%, n (%)

714 (52.1)

409 (55.2)

 

  ≥ 7%, n (%)

657 (47.9)

332 (44.8)

 

eGFR (mL/min/1.73m2)

54.3 ± 22.2

54.7 ± 22.0

0.35

Patients with fractures, n (%)

17 (1.2)

52 (7.0)

< 0.001

Number of drugs being administered at the time of hospitalization (agents)

7.7 ± 3.9

7.7 ± 3.7

0.4

Patients not using hypoglycemic agent, n (%)

415 (30.3)

285 (38.4)

< 0.001

Glinide, n (%)

0

0

SGLT2 inhibitors, n (%)

7 (0.5)

1 (0.1)

0.25

TZD, n (%)

109 (8.0)

39 (5.3)

0.04

αGI, n (%)

126 (9.2)

74 (10.0)

0.63

BG, n (%)

268 (19.5)

139 (18.8)

0.66

SU, n (%)

388 (28.3)

154 (20.8)

0.001

DPP-4 inhibitors, n (%)

609 (44.4)

295 (39.8)

0.06

GLP-1 receptor agonist, n (%)

26 (1.9)

13 (1.8)

0.84

Insulin, n (%)

295 (21.4)

145 (19.6)

0.38

  1. Mean ± S.D., BMI (body mass index), HbA1c (hemoglobin A1c), eGFR (estimated glomerular filtration rate), SGLT2 inhibitors (sodium glucose cotransporter 2 inhibitors), TZD (thiazolidines), αGI (α-glucosidase inhibitors), BG (biguanides), SU (sulfonylureas), DPP-4 inhibitors (dipeptidyl peptidase 4 inhibitors), GLP-1 receptor agonist (glucagon-like peptide-1 receptor agonist)